Literature DB >> 19819638

Hypercalcaemia and acute renal failure after major burns: An under-diagnosed condition.

Barbara Kohut1, Julien Rossat, Wassim Raffoul, Olivier Lamy, Mette M Berger.   

Abstract

BACKGROUND: Hypercalcaemia has been shown to occur in about 20% of patients with major burns requiring prolonged intensive care unit (ICU) treatment, and it may be associated with renal failure. Having observed the early onset of hypercalcaemia, the study aimed to determine the frequency and timing of this condition in a European patient cohort.
METHODS: A retrospective cohort study on a prospectively collected, computerised database of the 225 burn-injury ICU admissions between 2001 and 2007 was undertaken. The inclusion criteria included: burns >20% of the body surface area (BSA) or in-hospital stay >20 days. Hypercalcaemia was defined as an ionised plasma calcium (Ca(2+)) concentration >1.32 mmol l(-1) (or total corrected calcium=[Ca]c>2.55 mmol l(-1)). Four emblematic cases are reported in this article.
RESULTS: A total of 73 patients met the inclusion criteria (age: 13-88 years, burns: 12-85% BSA): of these, 22 (30%) developed hypercalcaemia. The median time to the first hypercalcaemia value was 21 days. Only 11 patients had both high Ca(2+) and elevated [Ca]c (which remained normal in others). The risk factors of the disorder were burned surface (p=0.017) and immobilisation (fluidised bed use: p<0.05, duration: p=0.02) followed by burned BSA. Acute renal failure tended to be more frequent in hypercalcaemic patients (five (23%) vs. three (6%): p=0.11), while mortality was not increased. The disorder resolved with hydration and mobilisation in most cases: pamidronate was successful in three cases that were most severe.
CONCLUSION: Hypercalcaemia and associated acute renal failure occur more frequently and earlier than previously reported. Determining the ionised Ca rather than the total Ca with albumin correction enables earlier detection of hypercalcaemia. Bisphosphonates are an effective treatment option in controlling severe hypercalcaemia and preventing bone loss. Copyright 2009 Elsevier Ltd and ISBI. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19819638     DOI: 10.1016/j.burns.2009.05.001

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  5 in total

1.  Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure.

Authors:  Michael P Whyte; Rattana Leelawattana; William R Reinus; Chang Yang; Steven Mumm; Deborah V Novack
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

2.  Denosumab for treatment of immobilization-related hypercalcaemia in a patient with advanced renal failure.

Authors:  Esther de Beus; Walther H Boer
Journal:  Clin Kidney J       Date:  2012-10-07

3.  Immobilization-Related Hypercalcemia in a COVID-19 Patient With Prolonged Intensive Care Unit Stay.

Authors:  Jean-Baptiste Mesland; Christine Collienne; Pierre-François Laterre; Philippe Hantson
Journal:  Am J Phys Med Rehabil       Date:  2022-01-01       Impact factor: 3.412

4.  Predictive value of ionized calcium in critically ill patients: an analysis of a large clinical database MIMIC II.

Authors:  Zhongheng Zhang; Xiao Xu; Hongying Ni; Hongsheng Deng
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

5.  Association of Initial Serum Total Calcium Concentration with Mortality in Critical Illness.

Authors:  Benji Wang; Yuqiang Gong; Binyu Ying; Bihuan Cheng
Journal:  Biomed Res Int       Date:  2018-06-26       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.